2013 January to June approved project brief news

【 Newsletter 1】

On June 26, 2013, Jiangsu Provincial Department of Finance and Jiangsu Provincial Agricultural Commission jointly issued A notice on the development of provincial modern agriculture - Agricultural industrialization project in 2013, and the "development and industrialization project of Newcastle Disease recombinant Virus inactivated vaccine (A-ⅶ strain)" declared by the company was among them, and the project obtained a provincial subsidy fund of 1 million yuan.

According to the latest research, Newcastle disease virus is the main pathogen that causes Newcastle disease in Chinese duck population in recent years, so the development and application of new Newcastle disease virus vaccine is urgent, and the development of Newcastle disease virus reverse genetic technology creates conditions for the development of new vaccines.

"Newcastle Disease recombinant virus inactivated vaccine (A-Ⅶ strain)" is an avian vaccine product developed by the company and Veterinary School of Yangzhou University through the cooperation platform of production, study and research. The School of Veterinary Medicine of Yangzhou University adopted advanced reverse genetic technology to rescue for the first time A vaccine candidate strain (A-ⅶ) with the same genotype as the epidemic strain. The recombinant NDV (A-ⅶ) was pure and free of foreign sources. At the same time, high titer virus antigen was obtained by concentrating and purifying with hollow fiber membrane. The product of the project relies on the recombinant Newcastle disease virus (A-Ⅶ strain) obtained from the Veterinary School of Yangzhou University as the seed virus, which is harvested by chicken embryo culture, and the seed batch is set up for production. After the chicken embryo proliferation, the harvested disease venom is concentrated, purified, inactivated, and then mixed with mineral oil to form an inactivated vaccine.

The market gap of Newcastle disease recombinant virus inactivated vaccine (A-ⅶ strain) is relatively large. Through the implementation of this project, the project products will meet the market demand to A greater extent, increase some employment opportunities, and to a certain extent protect the interests of farmers and people's life safety. At the same time, this project takes the lead in introducing large-scale concentration and purification production technology of antigen in the industry. Through the driving and demonstration role of this project, the company's animal vaccine production technology level can be close to that of developed countries, while promoting the overall production level of China's animal vaccine industry, it will bring benefits to enterprises, create profits and taxes for the country, and provide protection for people's health.

【 Newsletter 2】

After the examination and approval of Jiangyin Science and Technology Bureau and tax Bureau, Jiangsu Nannong High-tech Co., Ltd. continued to enjoy the preferential policies of provincial high-tech enterprises in 2012.

Since the company was identified as a provincial high-tech enterprise by Jiangsu Provincial Science and Technology Department in 2009, the company's brand image has been greatly improved, the ability of independent innovation of enterprises has been significantly enhanced, the business performance has risen significantly, and the status of enterprises in the industry has been continuously improved, which provides a strong qualification guarantee for enterprises in the market economy competition. It provides guarantee for the company to achieve sustainable development.